Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases

Research output: Contribution to journalArticle

Fernanda P. Pons-Faudoa, Andrea Ballerini, Jason Sakamoto, Alessandro Grattoni

Chronic diseases account for the majority of all deaths worldwide, and their prevalence is expected to escalate in the next 10 years. Because chronic disorders require long-term therapy, the healthcare system must address the needs of an increasing number of patients. The use of new drug administration routes, specifically implantable drug delivery devices, has the potential to reduce treatment-monitoring clinical visits and follow-ups with healthcare providers. Also, implantable drug delivery devices can be designed to maintain drug concentrations in the therapeutic window to achieve controlled, continuous release of therapeutics over extended periods, eliminating the risk of patient non-compliance to oral treatment. A higher local drug concentration can be achieved if the device is implanted in the affected tissue, reducing systemic adverse side effects and decreasing the challenges and discomfort of parenteral treatment. Although implantable drug delivery devices have existed for some time, interest in their therapeutic potential is growing, with a global market expected to reach over $12 billion USD by 2018. This review discusses implantable drug delivery technologies in an advanced stage of development or in clinical use and focuses on the state-of-the-art of reservoir-based implants including pumps, electromechanical systems, and polymers, sites of implantation and side effects, and deployment in developing countries.

Original languageEnglish (US)
Article number47
JournalBiomedical Microdevices
Volume21
Issue number2
DOIs
StatePublished - Jun 1 2019

PMID: 31104136

Altmetrics

Cite this

Standard

Advanced implantable drug delivery technologies : transforming the clinical landscape of therapeutics for chronic diseases. / Pons-Faudoa, Fernanda P.; Ballerini, Andrea; Sakamoto, Jason; Grattoni, Alessandro.

In: Biomedical Microdevices, Vol. 21, No. 2, 47, 01.06.2019.

Research output: Contribution to journalArticle

Harvard

Pons-Faudoa, FP, Ballerini, A, Sakamoto, J & Grattoni, A 2019, 'Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases' Biomedical Microdevices, vol. 21, no. 2, 47. https://doi.org/10.1007/s10544-019-0389-6

APA

Pons-Faudoa, F. P., Ballerini, A., Sakamoto, J., & Grattoni, A. (2019). Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases. Biomedical Microdevices, 21(2), [47]. https://doi.org/10.1007/s10544-019-0389-6

Vancouver

Pons-Faudoa FP, Ballerini A, Sakamoto J, Grattoni A. Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases. Biomedical Microdevices. 2019 Jun 1;21(2). 47. https://doi.org/10.1007/s10544-019-0389-6

Author

Pons-Faudoa, Fernanda P. ; Ballerini, Andrea ; Sakamoto, Jason ; Grattoni, Alessandro. / Advanced implantable drug delivery technologies : transforming the clinical landscape of therapeutics for chronic diseases. In: Biomedical Microdevices. 2019 ; Vol. 21, No. 2.

BibTeX

@article{3d4d4a28508c4c2fb72be6b4f33f30cb,
title = "Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases",
abstract = "Chronic diseases account for the majority of all deaths worldwide, and their prevalence is expected to escalate in the next 10 years. Because chronic disorders require long-term therapy, the healthcare system must address the needs of an increasing number of patients. The use of new drug administration routes, specifically implantable drug delivery devices, has the potential to reduce treatment-monitoring clinical visits and follow-ups with healthcare providers. Also, implantable drug delivery devices can be designed to maintain drug concentrations in the therapeutic window to achieve controlled, continuous release of therapeutics over extended periods, eliminating the risk of patient non-compliance to oral treatment. A higher local drug concentration can be achieved if the device is implanted in the affected tissue, reducing systemic adverse side effects and decreasing the challenges and discomfort of parenteral treatment. Although implantable drug delivery devices have existed for some time, interest in their therapeutic potential is growing, with a global market expected to reach over $12 billion USD by 2018. This review discusses implantable drug delivery technologies in an advanced stage of development or in clinical use and focuses on the state-of-the-art of reservoir-based implants including pumps, electromechanical systems, and polymers, sites of implantation and side effects, and deployment in developing countries.",
keywords = "Implants, Long-acting formulations, MEMS, NEMS, Non-biodegradable polymers",
author = "Pons-Faudoa, {Fernanda P.} and Andrea Ballerini and Jason Sakamoto and Alessandro Grattoni",
year = "2019",
month = "6",
day = "1",
doi = "10.1007/s10544-019-0389-6",
language = "English (US)",
volume = "21",
journal = "Biomedical Microdevices",
issn = "1387-2176",
publisher = "Kluwer Academic Publishers",
number = "2",

}

RIS

TY - JOUR

T1 - Advanced implantable drug delivery technologies

T2 - Biomedical Microdevices

AU - Pons-Faudoa, Fernanda P.

AU - Ballerini, Andrea

AU - Sakamoto, Jason

AU - Grattoni, Alessandro

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Chronic diseases account for the majority of all deaths worldwide, and their prevalence is expected to escalate in the next 10 years. Because chronic disorders require long-term therapy, the healthcare system must address the needs of an increasing number of patients. The use of new drug administration routes, specifically implantable drug delivery devices, has the potential to reduce treatment-monitoring clinical visits and follow-ups with healthcare providers. Also, implantable drug delivery devices can be designed to maintain drug concentrations in the therapeutic window to achieve controlled, continuous release of therapeutics over extended periods, eliminating the risk of patient non-compliance to oral treatment. A higher local drug concentration can be achieved if the device is implanted in the affected tissue, reducing systemic adverse side effects and decreasing the challenges and discomfort of parenteral treatment. Although implantable drug delivery devices have existed for some time, interest in their therapeutic potential is growing, with a global market expected to reach over $12 billion USD by 2018. This review discusses implantable drug delivery technologies in an advanced stage of development or in clinical use and focuses on the state-of-the-art of reservoir-based implants including pumps, electromechanical systems, and polymers, sites of implantation and side effects, and deployment in developing countries.

AB - Chronic diseases account for the majority of all deaths worldwide, and their prevalence is expected to escalate in the next 10 years. Because chronic disorders require long-term therapy, the healthcare system must address the needs of an increasing number of patients. The use of new drug administration routes, specifically implantable drug delivery devices, has the potential to reduce treatment-monitoring clinical visits and follow-ups with healthcare providers. Also, implantable drug delivery devices can be designed to maintain drug concentrations in the therapeutic window to achieve controlled, continuous release of therapeutics over extended periods, eliminating the risk of patient non-compliance to oral treatment. A higher local drug concentration can be achieved if the device is implanted in the affected tissue, reducing systemic adverse side effects and decreasing the challenges and discomfort of parenteral treatment. Although implantable drug delivery devices have existed for some time, interest in their therapeutic potential is growing, with a global market expected to reach over $12 billion USD by 2018. This review discusses implantable drug delivery technologies in an advanced stage of development or in clinical use and focuses on the state-of-the-art of reservoir-based implants including pumps, electromechanical systems, and polymers, sites of implantation and side effects, and deployment in developing countries.

KW - Implants

KW - Long-acting formulations

KW - MEMS

KW - NEMS

KW - Non-biodegradable polymers

UR - http://www.scopus.com/inward/record.url?scp=85065867081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065867081&partnerID=8YFLogxK

U2 - 10.1007/s10544-019-0389-6

DO - 10.1007/s10544-019-0389-6

M3 - Article

VL - 21

JO - Biomedical Microdevices

JF - Biomedical Microdevices

SN - 1387-2176

IS - 2

M1 - 47

ER -

ID: 49042830